The CompCure Study:

Prospective cohort study on C3 glomerulopathy and IC-MPGN


C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney diseases caused by complement system defects or monoclonal immunoglobulin deposition. This leads to the accumulation of components in the kidney's filtration unit (glomerulus), potentially causing renal dysfunction and requiring dialysis.

Promisingly, new complement inhibitors are under development to improve management and outcomes for these conditions.

The project aims to collect data from affected individuals to better understand disease progression, classify patients for more effective treatments, and involve them in clinical trials. The primary objectives of the study include:

  • Establishing a patient cohort for C3G and IC-MPGN.
  • Creating a prospective registry to monitor disease progression.
  • Establishing a centralized biobank.
  • Conducting expert pathology reviews.

Additionally, newly diagnosed or poorly documented patients will undergo a comprehensive assessment, including immunodiagnostic and genetic tests, conducted at specialized reference laboratories. Any costs not covered by national health insurance will be covered by CompCure to ensure affordability for all patients.

Design:Pro- and retrospective observational study
Patients enrolled:Enrolment ongoing
Inclusion Criteria:Pediatric and adult patients affected by C3G/MPGN
Exclusion Criteria:Secondary C3G/MPGN
Coordinating Center:University Hospital Heidelberg
More information:

Contact Information: